Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KMT2C mutation as a predictor of immunotherapeutic efficacy in colorectal cancer.

Scientific reports - 9 Apr 2024

Ni Chunhua, Wang Xiaohong, Liu Shaoping, Zhang Junling, Luo Zhongguang, Xu Bei

Abstract excerpt

Immunotherapy had shown good antitumor activity in a variety of solid tumors, but low benefit in CRC, so there was an urgent need to explore new biomarkers. We evaluated the role of KMT2C using publicly available data from the Cancer Genome Atlas (TCGA) and Memorial Sloan Kettering Cancer Center (MSKCC). In addition, further analysis was performed in an internal cohort. Moreover, the mutant profiles of KMT2C was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Biomarkers, Tumor
Share to Cancer Immunotherapy and Biomarkers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to Epigenetics and DNA Methylation

Share to Ferroptosis and cancer prognosis

Share to Immunotherapy

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 38594266
DOI: 10.1038/s41598-024-57519-8
PMCID: PMC11004165

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KMT2C mutation as a predictor of immunotherapeutic efficacy in colorectal cancer.PMID 38594266Read ↗

KMT2A/C mutations function as a potential predictive biomarker for immunotherapy in solid tumorsSemantic proximity Read ↗

Association of KMT2C/D loss-of-function variants with response to immune checkpoint blockades in colorectal cancer.Semantic proximity Read ↗

KMT2C is a Potential Biomarker of Anti-PD-1 Treatment Response in Metastatic Melanoma.Semantic proximity Read ↗

Correlation of KMT2 family mutations with molecular characteristics and prognosis in colorectal cancer.Semantic proximity Read ↗

Effects of KMT2D mutation and its exon 39 mutation on the immune microenvironment and drug sensitivity in colorectal adenocarcinomaSemantic proximity Read ↗

KMT2C is Potential Prognostic Biomarker and its Immune Regulating Roles in Pan-Cancer: A Comprehensive AnalysisSemantic proximity Read ↗

Mutation status of the KMT2 family associated with immune checkpoint inhibitors (ICIs) therapy and implicating diverse tumor microenvironmentsSemantic proximity Read ↗

Identification and Comprehensive Analysis of FREM2 Mutation as a Potential Prognostic Biomarker in Colorectal CancerSemantic proximity Read ↗

Novel tumor mutation score versus tumor mutation burden in predicting survival after immunotherapy in pan-cancer patients from the MSK-IMPACT cohortSemantic proximity Read ↗

Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer.Semantic proximity Read ↗

Genomic alterations in KMT2 family predict outcome of immune checkpoint therapy in multiple cancersSemantic proximity Read ↗

<i>MLL4/KMT2D</i> mutations increase immune activity and predict therapy efficacy in colorectal cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.